Treace Medical Concepts, Inc. Stock News

Treace Medical Concepts (TMCI) said the U.S. Patent and Trademark Office granted a patent to the company on instrumented bunion correction.The U.S

PONTE VEDRA, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a

The stock price of Treace Medical Concepts, Inc. (NASDAQ: TMCI) increased by 14.86% in the most recent trading session. This is why it happened.

Treace Medical Concepts (TMCI) provided preliminary unaudited results for fourth quarter and full year 2021.The company expects net sales for the fourth quarter and full year 2021 to be…

PONTE VEDRA, Fla., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in th

PONTE VEDRA, Fla., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Director James T. Treace sold 16,119 shares of the businesss stock in a transaction that occurred on Monday, December 20th. The shares were sold at an average price of $15.70, for a total value of $253,068.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, [] The post James T. Treace Sells 16,119 Shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI) Stock appeared first on ETF Daily News .

Treace Medical Concepts, Inc. (NASDAQ:TMCI) CEO John T. Treace sold 22,911 shares of Treace Medical Concepts stock in a transaction dated Monday, December 20th. The stock was sold at an average price of $15.75, for a total value of $360,848.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is [] The post John T. Treace Sells 22,911 Shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI) Stock appeared first on ETF Daily News .

Related Stocks: TMCI ,

Zacks Investment Research lowered shares of Treace Medical Concepts (NASDAQ:TMCI) from a hold rating to a sell rating in a report released on Wednesday morning, Zacks.com reports. According to Zacks, Treace Medical Concepts Inc. is a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus. Treace Medical Concepts []

Zacks Investment Research cut shares of Treace Medical Concepts (NASDAQ:TMCI) from a hold rating to a sell rating in a research report released on Wednesday, Zacks.com reports. According to Zacks, Treace Medical Concepts Inc. is a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus. Treace Medical Concepts []

Treace Medical Concepts, Inc. (NASDAQ:TMCI) hit a new 52-week low during mid-day trading on Monday following insider selling activity. The company traded as low as $15.12 and last traded at $15.12, with a volume of 9249 shares trading hands. The stock had previously closed at $16.54. Specifically, Director James T. Treace sold 75,000 shares of [] The post Treace Medical Concepts (NASDAQ:TMCI) Reaches New 1-Year Low on Insider Selling appeared first on ETF Daily News .

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Director James T. Treace sold 75,000 shares of the businesss stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $16.06, for a total transaction of $1,204,500.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this []

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Director James T. Treace sold 75,000 shares of the businesss stock in a transaction dated Wednesday, December 15th. The shares were sold at an average price of $16.06, for a total transaction of $1,204,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible []

Emerald Advisers LLC increased its stake in shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI) by 0.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 271,877 shares of the companys stock after buying an additional 1,470 shares during the quarter. Emerald Advisers []